References
- Kantarjian HM, Talpaz M, Giles F, O’Brien S, Cortes J. New insights into the pathophysiology of chronicmyeloid leukemia and imatinib resistance. Ann InternMed 2006;145(12):913–23.
- Goldman JM, Melo JV. BCR-ABL in chronic myelogenous leukemia–howdoes it work? Acta Haematol 2008;119(4):212–7.
- Sattler M, Griffin JD. Molecular mechanisms of transformation bythe BCR-ABL oncogene. Semin Hematol 2003;40(2Suppl 2):4–10.
- Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL forthe treatment of imatinib-resistant chronic myeloid leukaemia. NatRev Cancer 2007;7(5):345–56.
- Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al.. Efficacy and safety of a specific inhibitorof the BCR-ABL tyrosine kinase in chronic myeloid leukemia. NEngl J Med 2001;344(14):1031–7.
- Deininger MW. Milestones and monitoring in patients withCML treated with imatinib. Hematology Am Soc HematolEduc Program 2008:419–26.
- Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al.. High frequency of point mutations clusteredwithin the adenosine triphosphate-binding region of BCR/ABL in patients withchronic myeloid leukemia or ph-positive acute lymphoblastic leukemia who developimatinib (STI571) resistance. Blood 2002;99(9):3472–5.
- Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistanceto imatinib in chronic myeloid leukemia. Cancer Control 2009;16(2):122–31.
- Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinibtreatment for chronic myeloid leukemia: what is the optimal strategy? MayoClin Proc 2009;84(2):161–9.
- Zhou LL, Zhao Y, Ringrose A, DeGeer D, Kennah E, Lin AE, et al.. AHI-1 interacts with BCR-ABL and modulatesBCR-ABL transforming activity and imatinib response of CML stem/progenitorcells. J Exp Med 2008;205(11):2657–71.
- Jiang X, Zhao Y, Chan WY, Vercauteren S, Pang E, Kennedy S, et al.. Deregulated expression in ph+human leukemias of AHI-1, a gene activated by insertional mutagenesis in mousemodels of leukemia. Blood 2004;103(10):3897–904.
- Kennah E, Ringrose A, Zhou LL, Esmailzadeh S, Qian H, Su MW, et al.. Identification of tyrosine kinase,HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogenein primary and transformed CTCL cells. Blood 2009;113(19):4646–55.
- Li S. Src-family kinases in the development andtherapy of philadelphia chromosome-positive chronic myeloid leukemia and acutelymphoblastic leukemia. Leuk Lymphoma 2008;49(1):19–26.